Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
25.4 USD -0.55% Intraday chart for Anika Therapeutics, Inc. -0.74% +12.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating MT
Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Anika Therapeutics Swings to Q4 Earnings As Revenue Rises; to Cut 9% Workforce MT
Anika Therapeutics Guides For FY 2024 Revenue of $168-$173 Million, vs CIQ Analyst Consensus of $179 Million MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q4 EPS $0.05, vs. Street Est of $-0.23 MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q4 Revenue $43M, vs. Street Est of $41.4M MT
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Anika Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Activist investor Caligan discloses 9.7% stake in Anika, nominates two director candidates RE
Caligan Partners LP Issues Notice of Nominations to Anika Therapeutics, Inc CI
Anika Therapeutics, Inc. Announces Board Changes CI
Barrington Ups Price Target on Anika Therapeutics to $29 From $28, Reiterates Outperform Rating MT
Anika Therapeutics Says Surgeries Using Integrity Implant System Successful MT
Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System CI
Barrington Ups PT on Anika Therapeutics to $28 From $24, Expecting JPR Business to Produce 'Double-digit, Top-line Growth', Maintains Outperform Rating MT
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on April 13, 2023. CI
Transcript : Anika Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q3 EPS $0.00, vs. Street Est of $-0.35 MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q3 Revenue $41.5M, vs. Street Est of $38.3M MT
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023 CI
Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Anika Therapeutics, Inc. Announces the Full Market Release of the Revomotion Reverse Shoulder Arthroplasty System CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from S&P Biotechnology Select Industry Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from S&P 600 CI
Chart Anika Therapeutics, Inc.
More charts
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.4 USD
Average target price
30.33 USD
Spread / Average Target
+19.42%
Consensus
  1. Stock
  2. Equities
  3. Stock Anika Therapeutics, Inc. - Nasdaq
  4. News Anika Therapeutics, Inc.
  5. Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair